Phase 2 Study of Carboplatin, Docetaxel, and Bevacizumab as Frontline Treatment for Advanced Nonsmall-Cell Lung Cancer

BACKGROUND: Bevacizumab has recently been demonstrated to prolong overall survival when added to carboplatin and paclitaxel for chemotherapy-naïve patients with nonsquamous nonsmall-cell lung cancer (NSCLC). However, the effects of combining bevacizumab with other standard, front-line, platinum-base...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer
Autors principals: William, William N., Kies, Merrill S., Fossella, Frank V., Liu, Diane D., Gladish, Gregory, Tse, Warner H., Lee, J. Jack, Hong, Waun K., Lippman, Scott M., Kim, Edward S.
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5145307/
https://ncbi.nlm.nih.gov/pubmed/20225327
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24996
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars